temozolomide has been researched along with nutlin-3a in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kayama, T; Kitanaka, C; Matsuda, K; Sato, A; Seino, S; Sunayama, J; Suzuki, K; Tachibana, K; Tomiyama, A; Watanabe, E | 1 |
| Bossert, C; Chastagner, P; Dontenwill, M; Entz-Werle, N; Godet, J; Guenot, D; Guerin, E; Janouskova, H; Leger, DY; Lehmann-Che, J; Maglott, A; Martin, S; Noulet, F; Pinel, S; Plenat, F; Teisinger, J | 1 |
| Bailey, BJ; Bringman, LR; Cai, S; Cai, W; Cohen-Gadol, AA; Ding, J; Eitel, JA; Gelbert, LM; Georgiadis, TM; Gordon, KR; Jones, DR; Long, EC; Mayo, LD; Minto, RE; Murray, ME; Pollok, KE; Reza Saadatzadeh, M; Sarkaria, JN; Sen, SE; Shannon, HE; Tonsing-Carter, E; Wang, H; Waning, DL; Wells, CD; Zachary Gunter, T | 1 |
| Barone, D; Capone, F; Cirillo, D; Di Marzo, D; Forte, IM; Giordano, A; Iannuzzi, CA; Indovina, P; Pentimalli, F | 1 |
4 other study(ies) available for temozolomide and nutlin-3a
| Article | Year |
|---|---|
MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Topics: Aminoacetonitrile; Animals; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imidazoles; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-mdm2; RNA Interference; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Integrin alpha5beta1; Mice; Piperazines; Temozolomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Glioblastoma; Humans; Imidazoles; Piperazines; Proto-Oncogene Proteins c-mdm2; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Furans; Glioblastoma; Humans; Imidazoles; Mutation; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Temozolomide; Tumor Suppressor Protein p53 | 2019 |